UNLABELLED: A recent study from our laboratory found that (18)F-FIMX is an excellent PET radioligand for quantifying metabotropic glutamate receptor 1 (mGluR1) in monkey brain. This study evaluated the ability of (18)F-FIMX to quantify mGluR1 in humans. A second goal was to use the relative density of mGluR1 gene transcripts in brain regions to estimate specific uptake and nondisplaceable uptake (VND) in each brain region. METHODS: After injection of 189 ± 3 MBq of (18)F-FIMX, 12 healthy volunteers underwent a dynamic PET scan over 120 min. For 6 volunteers, images were acquired until 210 min. A metabolite-corrected arterial input function was measured from the radial artery. Four other subjects underwent whole-body scanning to estimate radiation exposure. RESULTS: (18)F-FIMX uptake into the human brain was high (SUV = 4-6 in the cerebellum), peaked at about 10 min, and washed out rapidly. An unconstrained 2-tissue-compartment model fitted the data well, and distribution volume (VT) (mL⋅cm(-3)) values ranged from 1.5 in the caudate to 11 in the cerebellum. A 120-min scan provided stable VT values in all regions except the cerebellum, for which an acquisition time of at least 170 min was necessary. VT values in brain regions correlated well with mGluR1 transcript density, and the correlation suggested that VND of (18)F-FIMX was quite low (0.5 mL⋅cm(-3)). This measure of VND in humans was similar to that from a receptor blocking study in monkeys, after correcting for differences in plasma protein binding. Similar to other (18)F-labeled ligands, the effective dose was about 23 μSv/MBq. CONCLUSION: (18)F-FIMX can quantify mGluR1 in the human brain with a 120- to 170-min scan. Correlation of brain uptake with the relative density of mGluR1 transcript allows specific receptor binding of a radioligand to be quantified without injecting pharmacologic doses of a blocking agent.
UNLABELLED: A recent study from our laboratory found that (18)F-FIMX is an excellent PET radioligand for quantifying metabotropic glutamate receptor 1 (mGluR1) in monkey brain. This study evaluated the ability of (18)F-FIMX to quantify mGluR1 in humans. A second goal was to use the relative density of mGluR1 gene transcripts in brain regions to estimate specific uptake and nondisplaceable uptake (VND) in each brain region. METHODS: After injection of 189 ± 3 MBq of (18)F-FIMX, 12 healthy volunteers underwent a dynamic PET scan over 120 min. For 6 volunteers, images were acquired until 210 min. A metabolite-corrected arterial input function was measured from the radial artery. Four other subjects underwent whole-body scanning to estimate radiation exposure. RESULTS: (18)F-FIMX uptake into the human brain was high (SUV = 4-6 in the cerebellum), peaked at about 10 min, and washed out rapidly. An unconstrained 2-tissue-compartment model fitted the data well, and distribution volume (VT) (mL⋅cm(-3)) values ranged from 1.5 in the caudate to 11 in the cerebellum. A 120-min scan provided stable VT values in all regions except the cerebellum, for which an acquisition time of at least 170 min was necessary. VT values in brain regions correlated well with mGluR1 transcript density, and the correlation suggested that VND of (18)F-FIMX was quite low (0.5 mL⋅cm(-3)). This measure of VND in humans was similar to that from a receptor blocking study in monkeys, after correcting for differences in plasma protein binding. Similar to other (18)F-labeled ligands, the effective dose was about 23 μSv/MBq. CONCLUSION: (18)F-FIMX can quantify mGluR1 in the human brain with a 120- to 170-min scan. Correlation of brain uptake with the relative density of mGluR1 transcript allows specific receptor binding of a radioligand to be quantified without injecting pharmacologic doses of a blocking agent.
Authors: Vincent J Cunningham; Eugenii A Rabiner; Mark Slifstein; Marc Laruelle; Roger N Gunn Journal: J Cereb Blood Flow Metab Date: 2009-09-09 Impact factor: 6.200
Authors: J Logan; J S Fowler; N D Volkow; A P Wolf; S L Dewey; D J Schlyer; R R MacGregor; R Hitzemann; B Bendriem; S J Gatley Journal: J Cereb Blood Flow Metab Date: 1990-09 Impact factor: 6.200
Authors: Paolo Zanotti-Fregonara; Vanessa N Barth; Jeih-San Liow; Sami S Zoghbi; David T Clark; Emily Rhoads; Edward Siuda; Beverly A Heinz; Eric Nisenbaum; Bruce Dressman; Elizabeth Joshi; Debra Luffer-Atlas; Matthew J Fisher; John J Masters; Nancy Goebl; Steven L Kuklish; Cheryl Morse; Johannes Tauscher; Victor W Pike; Robert B Innis Journal: Eur J Nucl Med Mol Imaging Date: 2012-11-08 Impact factor: 9.236
Authors: Soumen Paul; Mohammad B Haskali; Jeih-San Liow; Sami S Zoghbi; Vanessa N Barth; Marcy Comly Kolodrubetz; Michelle R Bond; Cheryl L Morse; Robert L Gladding; Michael P Frankland; Nancy Kant; Lawrence Slieker; Sergey Shcherbinin; Hugh N Nuthall; Paolo Zanotti-Fregonara; John A Hanover; Cynthia Jesudason; Victor W Pike; Robert B Innis Journal: J Nucl Med Date: 2018-09-13 Impact factor: 10.057
Authors: Stefanie M A Willekens; Donatienne Van Weehaeghe; Philip Van Damme; Koen Van Laere Journal: Eur J Nucl Med Mol Imaging Date: 2016-12-08 Impact factor: 9.236
Authors: Jinsoo Hong; Shuiyu Lu; Rong Xu; Jeih-San Liow; Alicia E Woock; Kimberly J Jenko; Robert L Gladding; Sami S Zoghbi; Robert B Innis; Victor W Pike Journal: Nucl Med Biol Date: 2015-07-23 Impact factor: 2.408
Authors: Talakad G Lohith; Tetsuya Tsujikawa; Fabrice G Siméon; Mattia Veronese; Sami S Zoghbi; Chul Hyoung Lyoo; Yasuyuki Kimura; Cheryl L Morse; Victor W Pike; Masahiro Fujita; Robert B Innis Journal: J Cereb Blood Flow Metab Date: 2016-01-01 Impact factor: 6.200